背景:非酒精性脂肪肝�。╪on-alcoholic fatty liver disease,NAFLD）是以肝實(shí)質(zhì)細(xì)胞脂肪變性、脂肪貯積和炎癥反應(yīng)為主要特征,并且無過量飲酒史的慢性肝臟代謝性疾病。NAFLD從單純性脂肪肝、可發(fā)展成為非酒精性脂肪性肝炎（non-alcoholic steatohepatitis,NASH）、肝纖維化、肝硬化、甚至肝癌。NAFLD的發(fā)病率、死亡率逐年升高,并呈低齡化發(fā)病趨勢(shì)。盡管目前對(duì)NAFLD發(fā)病機(jī)制的研究取得了一定的進(jìn)展,但仍然缺乏有效的治療藥物。因此,尋找對(duì)NAFLD有效的治療藥物就顯得尤其關(guān)鍵。黃芩苷（Baicalin,BA）是一種具有抗炎、抗氧化、調(diào)血脂、免疫調(diào)節(jié)等多種藥理作用的黃酮類化合物。研究發(fā)現(xiàn)黃芩苷對(duì)多種原因引起的肝臟損傷有一定的保護(hù)作用。目的:探討黃芩苷及其納米脂質(zhì)體對(duì)小鼠非酒精性脂肪肝病的保護(hù)作用及可能的作用機(jī)制。方法:1.黃芩苷納米脂質(zhì)體的制備及表征鑒定以卵磷脂、膽固醇為膜材料,采用薄膜分散法制備黃芩苷納米脂質(zhì)體,并考察其微觀形態(tài)、粒徑分布、多分散系數(shù)、Zeta電位值、包封率和載藥量。2.黃芩苷納米脂質(zhì)體對(duì)NAFLD小鼠的保護(hù)作用將... 

【文章來源】：重慶醫(yī)科大學(xué)重慶市

【文章頁(yè)數(shù)】：72 頁(yè)

【學(xué)位級(jí)別】：碩士

【部分圖文】：

黃芩苷結(jié)構(gòu)式Fig1.ThemolecularstructuralformulaofBaicalin

圖 2. 黃芩苷納米脂質(zhì)體透射電鏡圖Transmission electron micrograph image o體的粒徑分布、多分散系數(shù)和苷納米脂質(zhì)體平均粒徑為 81.41 nm

圖 2. 黃芩苷納米脂質(zhì)體透射電鏡圖Fig 2. Transmission electron micrograph image of BA-NL苷納米脂質(zhì)體的粒徑分布、多分散系數(shù)和 Zeta 電位 3 所示，黃芩苷納米脂質(zhì)體平均粒徑為 81.41 nm，多分散系數(shù)值為-13.9 ± 5.74 mV。

【參考文獻(xiàn)】：
期刊論文
[1]Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression[J]. Enas A Abd El-Haleim,Ashraf K Bahgat,Samira Saleh.  World Journal of Gastroenterology. 2016(10)
[2]Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle,through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway[J]. XI You-Li,LI Hong-Xia,CHEN Chen,LIU Ya-Qun,LV Hong-Mei,DONG Shi-Qi,LUO Er-Fei,GU Ming-Bo,LIU Hua.  Chinese Journal of Natural Medicines. 2016(01)
[3]Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?[J]. Nicolas Lanthier.  World Journal of Hepatology. 2015(19)
[4]Recent advances in mouse models of obesity-and nonalcoholic steatohepatitis-associated hepatocarcinogenesis[J]. Hayato Nakagawa.  World Journal of Hepatology. 2015(17)
[5]Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Yoshihisa Takahashi,Keiichiro Sugimoto,Hiroshi Inui,Toshio Fukusato.  World Journal of Gastroenterology. 2015(13)
[6]黃芩苷乙基纖維素微球鼻腔給藥系統(tǒng)的制備研究[J]. 錢余義,張劉紅,郭立瑋,朱華旭,付廷明.  中國(guó)中藥雜志. 2014(24)
[7]Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?[J]. Puja Sakhuja.  World Journal of Gastroenterology. 2014(44)
[8]Non-alcoholic fatty liver disease: What the clinician needs to know[J]. Mariana Verdelho Machado,Helena Cortez-Pinto.  World Journal of Gastroenterology. 2014(36)
[9]膠態(tài)二氧化硅和多孔二氧化硅作為黃芩苷固體分散載體的比較[J]. 嚴(yán)紅梅,丁冬梅,汪晶,孫娥,賈曉斌,張振海.  中國(guó)中藥雜志. 2014(13)
[10]Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease[J]. Xue-Qun Zhang,Cheng-Fu Xu,Chao-Hui Yu,Wei-Xing Chen,You-Ming Li.  World Journal of Gastroenterology. 2014(07)



本文編號(hào)：3542760